SG11201808222RA - Methods of treatment of cholestatic diseases - Google Patents
Methods of treatment of cholestatic diseasesInfo
- Publication number
- SG11201808222RA SG11201808222RA SG11201808222RA SG11201808222RA SG11201808222RA SG 11201808222R A SG11201808222R A SG 11201808222RA SG 11201808222R A SG11201808222R A SG 11201808222RA SG 11201808222R A SG11201808222R A SG 11201808222RA SG 11201808222R A SG11201808222R A SG 11201808222RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cholestatic diseases
- english
- march
- pct
- Prior art date
Links
- 230000001587 cholestatic effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 229950001279 elafibranor Drugs 0.000 abstract 2
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 abstract 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 102100034633 Homeobox expressed in ES cells 1 Human genes 0.000 abstract 1
- 101100284798 Homo sapiens HESX1 gene Proteins 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- KGZJRXKGJRJKCB-UHFFFAOYSA-N hanf Chemical compound C=1C=CC=CC=1CC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(CS)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)CNC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)C(NC(=O)C(CS)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(C)C)NC(=O)C(N)CO)CC1=CC=CC=C1 KGZJRXKGJRJKCB-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 11111111011110111010101111101011111011101111111111111110111101111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/167935 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/192 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61P 1/16 (2006.01) A61K 45/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/EP2017/057634 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 30 March 2017 (30.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 16305381.2 31 March 2016 (31.03.2016) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Avinee, 59120 LOOS (FR). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventor: HANF, Remy; 13 rue Princesse, 59000 LILLE LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (FR). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (74) Agent: CABINET BECKER ET ASSOCIES; 25, me Published: Louis le Grand, 75002 PARIS (FR). — with international search report (Art. 21(3)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Il ir) M CT IN 1-1 IN 1-1 © (54) Title: METHODS OF TREATMENT OF CHOLESTATIC DISEASES el (57) : The present invention relates to the use of compound 1 -[4-methylthiophenyl]-3-[3,5- dimethy1-4-carboxydimethyl- O methyloxyphenyl]prop-2-en-1 -one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305381 | 2016-03-31 | ||
| PCT/EP2017/057634 WO2017167935A1 (en) | 2016-03-31 | 2017-03-30 | Methods of treatment of cholestatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808222RA true SG11201808222RA (en) | 2018-10-30 |
Family
ID=55661352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808222RA SG11201808222RA (en) | 2016-03-31 | 2017-03-30 | Methods of treatment of cholestatic diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11185519B2 (en) |
| EP (2) | EP4233910A3 (en) |
| JP (1) | JP7010836B2 (en) |
| KR (1) | KR102338085B1 (en) |
| CN (2) | CN114796237B (en) |
| AU (1) | AU2017242819B2 (en) |
| BR (1) | BR112018069023A2 (en) |
| CA (1) | CA3018132C (en) |
| EA (1) | EA038386B1 (en) |
| IL (2) | IL311687A (en) |
| MX (2) | MX2018011738A (en) |
| PH (1) | PH12018502056A1 (en) |
| SG (1) | SG11201808222RA (en) |
| WO (1) | WO2017167935A1 (en) |
| ZA (1) | ZA201807084B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014010223B8 (en) | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | use of a composition comprising bile acid recycling inhibitors and pediatric dosage form |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| AU2018223976B2 (en) * | 2017-02-24 | 2023-08-17 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2019099761A1 (en) * | 2017-11-16 | 2019-05-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of elafibranor |
| WO2019186410A1 (en) * | 2018-03-27 | 2019-10-03 | Lupin Limited | Solid forms of elafibranor and processes thereof |
| EP3863623A1 (en) * | 2018-10-11 | 2021-08-18 | Centre national de la recherche scientifique | Treatment of diseases associated with biliary system destruction |
| EP3923970B1 (en) * | 2019-02-12 | 2024-05-15 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
| JP2022524820A (en) * | 2019-03-13 | 2022-05-10 | ノバルティス アーゲー | Pharmaceutical composition |
| CN110548118B (en) * | 2019-10-21 | 2021-09-14 | 江苏省中医院 | Traditional Chinese medicine compound for preventing and treating primary biliary cholangitis and preparation method and application thereof |
| AU2021220519A1 (en) * | 2020-02-10 | 2022-09-22 | Genfit | Treatment of primary biliary cholangitis with elafibranor |
| EP4153156A1 (en) * | 2020-05-18 | 2023-03-29 | Genfit | Elafibranor for the treatment of primary sclerosing cholangitis |
| JP2023539639A (en) | 2020-08-25 | 2023-09-15 | イーライ リリー アンド カンパニー | SSAO inhibitor polymorphism |
| AU2023272443A1 (en) * | 2022-05-19 | 2024-10-31 | Tyra Biosciences, Inc. | Therapies with ppar agonists and fgfr4 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841900B1 (en) | 2002-07-08 | 2007-03-02 | Genfit S A | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| US20070197606A1 (en) * | 2006-02-22 | 2007-08-23 | Burczynski Frank J | Use of ppar agonists as anti-oxidants |
| EA020849B1 (en) * | 2009-11-26 | 2015-02-27 | Женфит | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| CN107405325B (en) * | 2015-02-06 | 2021-11-12 | 英特塞普特医药品公司 | Pharmaceutical compositions for combination therapy |
| AU2018223976B2 (en) * | 2017-02-24 | 2023-08-17 | Genfit | Pharmaceutical compositions for combination therapy |
-
2017
- 2017-03-30 EA EA201892202A patent/EA038386B1/en unknown
- 2017-03-30 JP JP2018550793A patent/JP7010836B2/en active Active
- 2017-03-30 KR KR1020187031600A patent/KR102338085B1/en active IP Right Grant
- 2017-03-30 EP EP23175851.7A patent/EP4233910A3/en active Pending
- 2017-03-30 MX MX2018011738A patent/MX2018011738A/en unknown
- 2017-03-30 MX MX2021015783A patent/MX2021015783A/en unknown
- 2017-03-30 AU AU2017242819A patent/AU2017242819B2/en active Active
- 2017-03-30 WO PCT/EP2017/057634 patent/WO2017167935A1/en active Application Filing
- 2017-03-30 IL IL311687A patent/IL311687A/en unknown
- 2017-03-30 CN CN202210467808.5A patent/CN114796237B/en active Active
- 2017-03-30 BR BR112018069023A patent/BR112018069023A2/en not_active Application Discontinuation
- 2017-03-30 SG SG11201808222RA patent/SG11201808222RA/en unknown
- 2017-03-30 CN CN201780020144.5A patent/CN109152756B/en active Active
- 2017-03-30 IL IL261935A patent/IL261935B2/en unknown
- 2017-03-30 US US16/090,415 patent/US11185519B2/en active Active
- 2017-03-30 EP EP17713332.9A patent/EP3435996A1/en active Pending
- 2017-03-30 CA CA3018132A patent/CA3018132C/en active Active
-
2018
- 2018-09-25 PH PH12018502056A patent/PH12018502056A1/en unknown
- 2018-10-24 ZA ZA2018/07084A patent/ZA201807084B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114796237B (en) | 2024-02-23 |
| KR20180126574A (en) | 2018-11-27 |
| EP3435996A1 (en) | 2019-02-06 |
| ZA201807084B (en) | 2019-06-26 |
| IL311687A (en) | 2024-05-01 |
| CA3018132C (en) | 2024-02-13 |
| JP7010836B2 (en) | 2022-01-26 |
| EP4233910A2 (en) | 2023-08-30 |
| JP2019510046A (en) | 2019-04-11 |
| US11185519B2 (en) | 2021-11-30 |
| IL261935B2 (en) | 2024-09-01 |
| CA3018132A1 (en) | 2017-10-05 |
| PH12018502056A1 (en) | 2019-07-01 |
| US20190111012A1 (en) | 2019-04-18 |
| BR112018069023A2 (en) | 2019-01-29 |
| EA038386B1 (en) | 2021-08-19 |
| IL261935A (en) | 2018-10-31 |
| EA201892202A1 (en) | 2019-03-29 |
| CN109152756B (en) | 2022-05-17 |
| CN114796237A (en) | 2022-07-29 |
| AU2017242819B2 (en) | 2022-06-30 |
| IL261935B1 (en) | 2024-05-01 |
| MX2018011738A (en) | 2019-06-24 |
| CN109152756A (en) | 2019-01-04 |
| AU2017242819A1 (en) | 2018-10-11 |
| KR102338085B1 (en) | 2021-12-10 |
| EP4233910A3 (en) | 2024-01-17 |
| WO2017167935A1 (en) | 2017-10-05 |
| MX2021015783A (en) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases |